Psychedelics & Neurostimulation for Brain Rewiring | Dr. Nolan Williams

Psychedelics & Neurostimulation for Brain Rewiring

Summary

Dr. Nolan Williams, director of Stanford’s Brain Stimulation Lab, discusses cutting-edge treatments for depression combining transcranial magnetic stimulation (TMS) with psychedelics including psilocybin, ketamine, ibogaine, and MDMA. The conversation covers the neural circuitry of depression, the surprising role of the opioid system in ketamine’s antidepressant effects, and the emerging “Psychiatry 3.0” framework that reframes depression as a fixable circuit problem rather than a chemical imbalance. Key research from Dr. Williams’ lab challenges long-held assumptions about how both SSRIs and ketamine actually work.

---

Key Takeaways

• Depression is the most disabling condition worldwide — now listed as the 4th major risk factor for coronary artery disease alongside hypertension, high cholesterol, and diabetes
• The left dorsolateral prefrontal cortex (DLPFC) governs mood by regulating the anterior cingulate; in depression, this hierarchy is inverted — the cingulate precedes the DLPFC in timing, and TMS can restore normal order
• Ketamine’s antidepressant effect is largely opioid-mediated, not glutamatergic — blocking opioid receptors with 50mg naltrexone dramatically eliminated ketamine’s antidepressant effect without affecting dissociation
• SSRIs work, but not through serotonin replenishment — the “chemical imbalance” model is considered outdated; antidepressant effects likely arise from downstream neuroplasticity changes such as BDNF upregulation
• SAINT (Stanford Accelerated Intelligent Neuromodulation Therapy) can bring people out of severe depression in 1–5 days using intensive TMS without any pharmacology
• The DLPFC-heart connection is real and measurable — stimulating the left DLPFC decelerates heart rate ~10 BPM in a time-locked manner via a tract through the anterior cingulate → insula → amygdala → nucleus tractus solitarius → vagus nerve
• Psychedelics may work through neuroplasticity, not just the subjective experience — the “trip” may not be the primary therapeutic mechanism; underlying pharmacology (e.g., opioid receptor activity, BDNF/GDNF upregulation) appears essential
• Behavioral interventions like exhale-emphasized breathing, mindfulness, and exercise may access the same DLPFC-vagal circuit, though they lose efficacy as depression severity increases
• Memory reconsolidation in a highly plastic state may explain why psychedelics resolve long-standing trauma — re-experiencing a memory under psychedelics reconsolidates it differently

---

Detailed Notes

Depression: Scope and Biology

• Depression encompasses a wide spectrum: anhedonia, anxiety-dominant, psychomotor retardation, and more — likely representing distinct biotypes based on neuroimaging
• Moderate depression is roughly as disabling as an acute heart attack; severe depression is comparable to untreated terminal cancer
• Depression triples oral opioid requirements by day 4 post-surgery (e.g., knee replacement), suggesting depressed patients experience greater pain — likely both physical and emotional
• Unlike cardiology, psychiatry provides fewer tools as acuity increases (from outpatient → inpatient → emergency), with no diagnostic tests at the highest acuity levels

The DLPFC–Heart Circuit

• Pathway: Left DLPFC → anterior cingulate → insula → amygdala → nucleus tractus solitarius → vagus nerve → heart
• Stimulating the left DLPFC during a 2-second TMS train produces ~10 BPM heart rate deceleration at 1 second, time-locked to stimulation
• This effect is region-specific — stimulating motor or visual cortex produces no such effect
• Stimulating the right DLPFC produces acceleration, supporting hemispheric balancing of mood:
  • Left DLPFC excitation → antidepressant
  • Right DLPFC excitation → anti-manic
  • This is confirmed by the Human Connectome Project: stroke lesions causing depression map to left DLPFC; lesions causing mania map to right DLPFC

SAINT / Rapid TMS Protocol

• Full name: Stanford Accelerated Intelligent Neuromodulation Therapy (SAINT or SNT)
• Dense stimulation delivered over 5 consecutive days
• Targets the portion of the left DLPFC functionally connected to the subgenual anterior cingulate (emotion-processing region)
• Results: Patients achieve full remission (zeroed-out depression scales) within 1–5 days
• In treatment-responders, neuroimaging shows the DLPFC regains temporal precedence over the anterior cingulate — restoring the normal healthy brain timing pattern
• Some patients who remit early report spontaneous mindfulness-like states of present-moment awareness by the end of the week — an unreported anecdotal finding

Ketamine and the Opioid System

• Common assumption: ketamine works via NMDA receptor antagonism (glutamate system)
• Key study: 50mg naltrexone (opioid receptor blocker) given before a standard therapeutic ketamine infusion dramatically blocked the antidepressant effect — without altering dissociation
• This suggests the opioid system is necessary (though not sufficient) for ketamine’s antidepressant action
• Chronic opioid use appears pro-depressant over time despite acute antidepressant-like effects
• Separately, TMS-mediated pain relief was also blocked by IV naloxone, suggesting a shared opioid-mediated mechanism across brain stimulation and pharmacology

SSRIs and the “Chemical Imbalance” Model

• SSRIs are effective for depression, OCD, GAD, and panic — confirmed by many meta-analyses
• However, the delayed onset (days to weeks) suggests serotonin reuptake blockage itself isn’t the direct driver
• More likely mechanism: downstream neuroplasticity effects, including BDNF upregulation
• The “chemical imbalance / serotonin deficiency” model is considered scientifically outdated within psychiatry — though this was not widely communicated to the public until recent media coverage
• TMS achieves equivalent or faster antidepressant effects without altering serotonin at all, further undermining the serotonin-centric model

Psychiatry 3.0 Framework

• Psychiatry 1.0: Psychotherapy / psychoanalysis — focus on early experience and psychodynamics
• Psychiatry 2.0: Pharmacology / chemical imbalance — focus on neurotransmitter correction
• Psychiatry 3.0: Circuit-based — focus on recalibrating dysfunctional brain networks using neuromodulation or neuroplasticity-inducing compounds
• Key shift: Depression reframed as a recoverable circuit problem, not a permanent deficit — empowering patients with a sense of agency and the knowledge that remission is achievable

Psychedelics: Mechanism and Clinical Applications

• Psilocybin, MDMA, ibogaine, DMT, ketamine, and cannabis are all under study at Stanford’s Brain Stimulation Lab
• Neuroimaging shows lasting circuit-level changes in the subgenual/default mode network after psilocybin and ketamine — in the same regions affected by TMS — persisting long after the drug clears
• Memory reconsolidation under psychedelics may explain long-term resolution of PTSD symptoms — re-experiencing trauma in a highly neuroplastic state allows different reconsolidation
• Ibogaine and other psychedelics upregulate BDNF and GDNF, promoting neuroplasticity
• Active research question: Can non-hallucinogenic analogs of psychedelics retain antidepressant effects? Animal data (LSD analog) suggests possibly yes; human data pending
• The subjective “trip” may not be the primary mechanism — pharmacological properties independent of the psychological experience appear critical

Behavioral Interventions and Thresholds

• Breathwork (exhale-emphasized or slow cadence breathing), meditation, and exercise may access the DLPFC-vagal circuit and alleviate **